US FDA Advisory Committee Reboot (Part II): The Right Balance For Conflicts Of Interest
Executive Summary
After back-and-forth tinkering with CoI restrictions, CDER is still finding it challenging to seat the right experts. Maybe more realistic guidelines are needed.